Wegovy pill, the first FDA‑approved oral GLP‑1 for weight loss, is now available via WeightWatchers Med+ from $149 per month ...

Lilly asked the FDA to step in after claiming that testing it’s done suggests copycat versions of Zepbound may carry “unknown ...

People who quit taking popular GLP-1 drugs such as Ozempic might their jeopardize heart health, according to a new study.

Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, ...

A new study suggests heart health gains disappear in half the time it takes to build them up when people stop taking GLP-1 ...

The study findings may spark treatment innovations for depression and anxiety.

A service tailored to people with workplace-based insurance coverage represents a new way for Lilly to bypass insurers and ...

After losing significant ground to rival Eli Lilly in the GLP-1 space over the past two years, Novo Nordisk is defending the ...

GLP-1 medications, such as Ozempic and Wegovy, are injected into the fatty layer beneath the skin to manage blood sugar and aid in weight management. The recommended injection sites include the ...

Researchers found that GLP-1 medicines caused weight loss mainly through fat reduction, with only modest decreases in ...

Nothing lasts forever, including the pounds shed in a GLP-1 program. A major study published this week finds that people who stop taking weight-loss injections regain all the weight they originally ...

A previous version of this story had an incorrect title for Brian Dunkin. He is the chief medical officer of endoscopy at Boston Scientific. The story has been corrected. Millions of Americans have ...